Published in Am J Respir Crit Care Med on November 01, 1995
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax (2005) 1.95
Effects of depressive symptoms on health-related quality of life in asthma patients. J Gen Intern Med (2000) 1.41
Categorizing asthma severity: an overview of national guidelines. Clin Med Res (2004) 1.27
Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax (1996) 1.27
Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J (2014) 0.97
Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time. Thorax (1998) 0.89
Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br J Clin Pharmacol (1999) 0.89
Optimal management of severe/refractory asthma. Clin Med Insights Circ Respir Pulm Med (2011) 0.86
Measuring health-related quality of life in patients with chronic obstructive pulmonary disease in a routine hospital setting: feasibility and perceived value. Health Qual Life Outcomes (2003) 0.86
Recommendation for optimal management of severe refractory asthma. J Asthma Allergy (2010) 0.81
Modeling asthma exacerbations through lung function in children. J Allergy Clin Immunol (2012) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Classifying asthma severity and treatment determinants: national guidelines revisited. Malays Fam Physician (2008) 0.75
Treatment of chronic severe asthma. West J Med (1997) 0.75
Oral-steroid sparing effect of inhaled fluticasone propionate in children with steroid-dependent asthma. Paediatr Child Health (2000) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med (2000) 5.82
Ragweed immunotherapy in adult asthma. N Engl J Med (1996) 4.69
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med (1998) 2.96
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol (2000) 2.51
Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med (2000) 2.29
Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med (2000) 2.18
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med (1992) 2.10
Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest (1989) 1.97
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med (1998) 1.85
A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest (1994) 1.83
Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med (1997) 1.72
Association of rhinovirus infections with asthma. Clin Microbiol Rev (1999) 1.70
The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents. J Allergy Clin Immunol (1998) 1.68
Comparison of airway and blood eosinophil function after in vivo antigen challenge. J Immunol (1992) 1.63
Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy (2006) 1.62
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol (1995) 1.58
Evolution of dry powder inhaler design, formulation, and performance. Respir Med (2002) 1.55
Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr (1998) 1.52
Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest (1999) 1.51
Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med (1999) 1.50
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol (1999) 1.46
Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol (1995) 1.43
Administration errors with a conventional metered dose inhaler versus a novel breath actuated device. Ann Allergy (1993) 1.42
The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med (1999) 1.42
Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J (1998) 1.39
Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol (1997) 1.38
Rhinovirus enters but does not replicate inside monocytes and airway macrophages. J Immunol (1996) 1.37
Hypothesis: decreased use of pediatric aspirin has contributed to the increasing prevalence of childhood asthma. Ann Allergy Asthma Immunol (1998) 1.33
The correlation between asthma control and health status: the GOAL study. Eur Respir J (2006) 1.33
Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis (1992) 1.33
Peanut oil is not allergenic to peanut-sensitive individuals. J Allergy Clin Immunol (1981) 1.32
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol (2001) 1.32
Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med (1998) 1.30
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol (1997) 1.29
Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response. Science (1976) 1.27
In vivo and in vitro studies on the use of the guinea pig as a model for virus-provoked airway hyperreactivity. Am Rev Respir Dis (1985) 1.27
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
NIH conference. Asthma. Ann Intern Med (1994) 1.22
Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol (1996) 1.21
Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy (2008) 1.20
Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels. Arch Intern Med (1978) 1.18
Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol (2000) 1.17
Early life origins of asthma. J Clin Invest (1999) 1.17
Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis (1991) 1.17
Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. J Allergy Clin Immunol (2000) 1.15
Transient protein-losing enteropathy and enlarged gastric rugae in childhood. Am J Dis Child (1981) 1.15
Parainfluenza virus-induced persistence of airway inflammation, fibrosis, and dysfunction associated with TGF-beta 1 expression in brown Norway rats. Am J Respir Crit Care Med (1996) 1.15
Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol (1999) 1.15
The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. J Allergy Clin Immunol (2000) 1.14
Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. Roles of CD18 and intercellular adhesion molecule-1. J Immunol (1996) 1.13
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs (1983) 1.12
Cytokine profiles of stimulated blood lymphocytes in asthmatic and healthy adolescents across the school year. J Interferon Cytokine Res (1997) 1.12
Decreased granulocyte response to isoproterenol in asthma during upper respiratory infections. Am Rev Respir Dis (1977) 1.12
The immediate and late allergic response to segmental bronchopulmonary provocation in asthma. Am J Respir Crit Care Med (1997) 1.11
The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med (1998) 1.11
The effect of segmental bronchoprovocation with allergen on airway lymphocyte function. Am J Respir Crit Care Med (1997) 1.11
The role of viral infections in the natural history of asthma. J Allergy Clin Immunol (2000) 1.09
Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am J Respir Crit Care Med (1995) 1.09
Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. Am Rev Respir Dis (1991) 1.08
IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis (1993) 1.08
Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion. Allergy (2006) 1.07
Rhinovirus produces nonspecific activation of lymphocytes through a monocyte-dependent mechanism. J Immunol (1996) 1.07
Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol (2000) 1.06
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol (1998) 1.06
Differential regulation of eosinophil adhesion and transmigration by pulmonary microvascular endothelial cells. J Immunol (1998) 1.05
Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics (2000) 1.04
Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. J Immunol (1995) 1.04
Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol (1998) 1.04
Parainfluenza 3 infection blocks the ability of a beta adrenergic receptor agonist to inhibit antigen-induced contraction of guinea pig isolated airway smooth muscle. J Clin Invest (1981) 1.03
Enhanced production of oxygen radicals in nocturnal asthma. Am Rev Respir Dis (1992) 1.03
Asthma. JAMA (1997) 1.02
Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J Allergy Clin Immunol (1988) 1.01
Soybean oil is not allergenic to soybean-sensitive individuals. J Allergy Clin Immunol (1985) 1.00
Impairment of isoproterenol, H2 histamine, and prostaglandin E1 response of human granulocytes after incubation in vitro with live influenza vaccines. Am Rev Respir Dis (1979) 1.00
Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med (1997) 1.00
Effect of isolation protocol on eosinophil function: Percoll gradients versus immunomagnetic beads. J Immunol Methods (1996) 0.99
Acremonium strictum-related pulmonary infection in a patient with chronic granulomatous disease. J Infect Dis (1984) 0.98
Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med (2009) 0.98
Increased airway inflammation with segmental versus aerosol antigen challenge. Am Rev Respir Dis (1993) 0.98
Decreased H2 histamine response of granulocytes of asthmatic patients. J Clin Invest (1977) 0.97
Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol (1999) 0.97
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med (1999) 0.96
Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol (1999) 0.96
Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. J Fam Pract (1996) 0.96
The appearance of hypodense eosinophils in antigen-dependent late phase asthma. Am Rev Respir Dis (1989) 0.96
Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med (1997) 0.96
Correlates of mammography among women with low and high socioeconomic resources. Prev Med (1995) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Isoproterenol inhibition of isolated human neutrophil function. J Allergy Clin Immunol (1984) 0.95